A Comparative Study of Approved Drugs for SARS-CoV-2 by Molecular Docking

Achal Mishra, Radhika Waghela

Department of Pharmaceutical Sciences, Shri Shankaracharya Technical Campus, Chhattisgarh Swami Vivekanand Technical University, Bhilai, Chhattisgarh, India

*email: achal.mishra03@gmail.com

Keywords:
Chloroquine
Favipiravir
Hydroxychloroquine
Lopinavir
Molecular docking
Remdesivir
SARS-CoV-2

Abstract
SARS-CoV-2, a new type of Coronavirus, has affected more millions of people worldwide. From the spread of this infection, many studies related to this virus and drug designing for the treatment have been started. Most of the studies target the SARS-CoV-2 main protease, spike protein of SARS-CoV-2, and some are targeting the human furin protease. In the current work, we chose the clinically used drug molecules remdesivir, favipiravir, lopinavir, hydroxychloroquine, and chloroquine onto the target protein SARS-CoV-2 main protease. Docking studies were performed using ArgusLab, while Discovery Studio collected 2D and 3D pose views with the crystal structure of COVID-19 main protease in complex with an inhibitor N3 with PDB ID 6LU7. Computational studies reveal that all ligands provided good binding affinities towards the target protein. Among all the chosen drugs, lopinavir showed the highest docking score of -11.75 kcal/mol. The results from this molecular docking study encourage the use of lopinavir as the first-line treatment drug due to its highest binding affinity.

Received: February 19th, 2021
Accepted: June 12th, 2021
Published: June 30th, 2021

INTRODUCTION
Coronavirus is a single-stranded RNA type of viruses, and in humans, this causes respiratory diseases varying from the common cold to severe/fatal illnesses. There are three types of coronaviruses which infected the human, associated with deadly phenomena. Starting with severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV), and now Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)13. The first case of SARS-CoV-2 was found in China, and it has killed millions of people worldwide from November 2020 to February 2021. The World Health Organization (WHO) announced Coronavirus disease (COVID-19) as the pandemic in 2020. The SARS-CoV-2 threat was spread in China and other countries rapidly. Thus, many efforts have been run to investigate suitable preventive and control strategies for COVID-19. Various available antiviral and antimicrobial drugs were used to treat human SARS-CoV-2, which are also used for treating previous Ebola, Zika, Nipah, MERS-CoVs, and SARS viruses. These antivirals are preferred because new drug and vaccine development requires more than 5 to 20 years. Therefore, researchers focused on available therapeutics, which have proven efficacy against viruses similar to COVID-19. These agents being used against SARS-CoV-2 treatment could be either virus-based, target viral S protein, some viral protease inhibitors, and some are receptor-binding domain–angiotensin-converting enzyme 2 (RBD–ACE2) blockers or host cell-based including host cell protease inhibitors and host cell endocytosis inhibitors. The spike proteins of SARS-CoV-2 carry S1 receptor binding subunit and S2 fusion subunit, and it directly arbitrates for viral entry with S1 site, which is essential for binding of host cell surface by ACE2. The binding
of the virus with the host cell surface is followed by S1/S2 cleave through host protease as TMPRSS2, cathepsins B and L. Studies on these particular drugs are currently undergoing tests for their efficacy and safety in treating COVID-19 worldwide. Despite the possible side effects, some positive and encouraging results have been achieved so far.

In the present study, we have investigated the binding of five active molecules, currently applied as the first-line treatment, favipiravir, hydroxychloroquine, remdesivir, lopinavir, and ritonavir, on one of the possible target proteins, RBD of SARS-CoV-2 main protease (Mpro) by molecular docking simulations. The selected drug, like remdesivir, is an antiviral prodrug of C-adenosine nucleoside analog GS-441524. It is metabolized in cells into active nucleoside triphosphate derivative, which intervenes in the activity of RNA-dependent RNA polymerase (RdRp) and further leads to the termination of viral RNA. Lopinavir is an antiviral drug, which inhibits viral protease. It was first approved in 2000 for the treatment of HIV infection. It is used in combination with ritonavir, which shows a synergistic effect improving its antiviral activity. Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral prodrug that was first used to treat influenza in Japan. It is also used to treat avian influenza (H5N1 influenza virus), Ebola, Lassa, Rabies, Bunyavirus, West Nile, and yellow fever viruses. Chloroquine and its derivative hydroxychloroquine were developed for the treatment of malaria. Chloroquine, along with its derivative hydroxychloroquine, is also used to treat HIV and rheumatoid arthritis. Chloroquine passively diffuses through the cell membrane into cell organelles like lysosomes and endosomes, where it is protonated, leading to an increase in the endosomal pH. This results in the abrogation of the virus-receptor binding and cell entry. From this background, through this research, we aim to elucidate target selection for future drug design studies for COVID-19.

**METHOD**

**Hardware and Software**

The software used was CORINA Classic from Molecular Networks GmbH and Altamira, LLC (https://www.mn-am.com/products/corina), ArgusLab 4.0.1 from Mark Thompson and Planaria Software LLC (http://www.arguslab.com/arguslab.com/ArgusLab.html), and Discovery Studio Visualizer v20.1.0.19295 from Dassault Systemes BIOVIA (https://www.3ds.com/products-services/biovia/products/molecular-modeling-simulation/biovia-discovery-studio/visualization).

**Ligands**

The compounds included in the study were remdesivir (PubChem ID 121304016), favipiravir (492405), lopinavir (92727), hydroxychloroquine (3652), and chloroquine (2719), which downloaded from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/).

**Receptors**

Docking simulations were performed with the X-ray structure of the crystal structure of SARS-CoV-2 Mpro in complex with an inhibitor N3 (PDB ID 6LU7), which downloaded from Protein Data Bank (https://www.rcsb.org).

**Docking protocol**

**Preparation of ligands**

The ligand structures were generated using the tool CORINA Classic. Three-dimensional optimizations of the ligand structures were done and saved as .mol file. Geometry optimizations of the ligands were performed according to the Hartree-Fock (HF) calculation method using ArgusLab 4.0.1.

**Preparation of protein**

The protein sequence was retrieved in the FASTA format, and the 3D structure was determined using the CPH model server. All water molecules were removed, and hydrogen atoms were added to the target protein molecule.

**Protein-ligand docking**

ArgusLab was an electronic structure program that was based on quantum mechanics. It predicts the potential energies, molecular structures, geometry optimization of the structure, vibration frequencies of coordinates of atoms, bond length, and bond angle. The selected bioactive antivirals were docked using ArgusLab Software. The interaction was carried out to find the favorable binding geometries of the ligand with the protein. Docking of the protein-ligand complex was mainly targeted only to the predicted active site. Docking simulations were performed by selecting “ArgusDock” as the docking engine. The selected residues of the receptor were defined to be a
part of the binding site. A spacing of 0.4 Å between the grid points was used, and an exhaustive search was performed by enabling the “High precision” option in the Docking precision menu, “Dock” was chosen as the calculation type, “flexible” for the ligand, and the “AScore” was used as the scoring function. A maximum of 150 poses was allowed to be analyzed; the binding site box size was 20 × 20 × 20 Å to encompass the entire active site. The A Score function, with the parameters read from the AScore.prm file, was used to calculate the binding energies of the resulting docked structures. All the ligands in the dataset were docked into the protein’s active site using the same protocol. The docking poses saved for each compound were ranked according to their docking score function. The pose having the highest docking score was selected for further analysis. Discovery Studio Visualizer was used for the visualization of 2D and 3D pose views.

RESULTS AND DISCUSSION

The affinity of ligands was presented by docking score (binding energy in kcal/mol), in which the more negative the value reflects the better binding affinity. All five ligands were docked against the target proteins, in which the nitrogen and oxygen atoms of the selected ligand were available for the hydrogen bond formation with the different amino acids of the target protein. When the docking of taken ligands was performed on the selected protein, the docking score for the ligands showed good binding affinity, as presented in Table I. Notably, lopinavir has the best binding affinity than other ligands with the selected protein with the lowest free energy of binding (ΔG) of -11.75 kcal/mol. Meanwhile, the ligand with the highest ΔG was favipiravir with -5.81 kcal/mol. Study of docking also suggested that amino acid residues His-246, Leu-253, Ile-152, Phe-8, Thr-292, Gln-110, and Asn-151 were the common residues, which participated in the different bond formation like hydrogen bond, Van der Waals bond, Pi-anion interaction, and these amino acid residues play a key role for bond formation with the selected protein target as shown in Figures 1 to 5.

Interactions on these amino acids have a distance of less than 3.0 Å, so the interactions that occur are worth considering.

| Ligands      | ΔG (kcal/mol) | Interacting atoms, amino acid residues, and the distance (Å) |
|--------------|---------------|------------------------------------------------------------|
| Lopinavir    | -11.75        | 1731-N;110-Gln; 2.19 Å                                     |
| Remdesivir   | -8.83         | 1731-O;110-Gln; 2.94 Å                                    |
| Chloroquine  | -8.7          | 1731-N;110-Gln; 2.71 Å                                    |
| Hydroxychloroquine | -8.39 | 1731-N;110-Gln; 2.94 Å                                    |
| Favipiravir  | -5.81         | 4278-O;280-Thr; 2.46 Å                                   |

Figure 1. (A) 2D and (B) 3D poses of lopinavir in SARS-CoV-2 MPro.
Figure 2. (A) 2D and (B) 3D poses of remdesivir in SARS-CoV-2 M(pro).

Figure 3. (A) 2D and (B) 3D poses of chloroquine in SARS-CoV-2 M(pro).

Figure 4. (A) 2D and (B) 3D poses of hydroxychloroquine in SARS-CoV-2 M(pro).
CONCLUSION

COVID-19 pandemic has been approached through various methods, involving newly developed vaccines under clinical trials. Since the in vivo and in vitro studies take a long time and effort, molecular docking of selective ligands and targets is helpful in these studies. Computational docking allowed us to find the binding affinity of the ligand with the target protein 6LU7. This finding shows the efficacy of the drugs in inhibiting the viral activity and spread of infection. In this comparative study, lopinavir showed the highest docking score of -11.75 kcal/mol, making it the most potent inhibitor among the other approved drugs. The results from this molecular docking study encourage the use of lopinavir as the first-line treatment drug due to its highest binding affinity.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare that are relevant to the content of this article.

FUNDING

None.

DATA AVAILABILITY

All data are available from the authors.

ACKNOWLEDGMENTS

The authors are thankful to the Faculty of Pharmaceutical Sciences Shri Shankaracharya Technical Campus Bhilai Chhattisgarh for providing the necessary infrastructure for the conduction of the work.

AUTHORS’ CONTRIBUTIONS

Achal Mishra: conceptualization, investigation, methodology, project administration, resources, software, supervision, writing – original draft, writing

Meanwhile, the docking of these ligands using ArgusLab with the 6LU7 receptor was first reported in this study, so the results of this study were expected to complement research data related to the following topics.

The results obtained were different from those reported by Eweas et al., who reported that remdesivir was more potent than lopinavir. However, the results of this study were consistent with those reported by Mothay & Ramesh, who reported better potency of lopinavir than remdesivir. It should be considered that the two studies used different software (Molegro Virtual Docker and AutoDock) than the one used in this study. The use of ArgusLab for docking against SARS-CoV-2 M^\text{pro} was reported by Das et al., but with a different PDB (6Y84).

Figure 5. (A) 2D and (B) 3D poses of favipiravir in SARS-CoV-2 M^\text{pro}.
REFERENCES

1. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. doi:10.1016/j.ijantimicag.2020.105951

2. Waals AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92. doi:10.1016/j.cell.2020.02.058

3. Wu C, Zheng M, Yang Y, Gu X, Yang K, Li M, et al. Furin: A Potential Therapeutic Target for COVID-19. iScience. 2020;23(10):101642. doi:10.1016/j.isci.2020.101642

4. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054. doi:10.1016/j.ijantimicag.2020.106054

5. Sohrabi C, Alsaﬁ Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-6. doi:10.1016/j.ijsu.2020.02.034

6. Dhma K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;16(6):1232-8. doi:10.1080/21645515.2020.1735227

7. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020;6(3):315-31. doi:10.1021/acscentsci.0c00272

8. Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cell Signal. 2020;74:109721. doi:10.1016/j.cellsig.2020.109721

9. Sharifkashani S, Bafrani MA, Khaboushan AS, Pirzadeh M, Kheirandish A, Bali HY, et al. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. Eur J Pharmacol. 2020;884:173455. doi:10.1016/j.ejphar.2020.173455

10. Nishima W, Kulik M. Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism. Viruses. 2021;13(6):1126. doi:10.3390/v13061126

11. Voit K, Timmermann C, Steger F. Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany – An Ethical Analysis. Int J Environ Res Public Health. 2021;18(11):5685. doi:10.3390/ijerph18115685

12. Yavuz SS, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(3):611-9. doi:10.3906/sag-2004-145

13. Drożdżał S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020;53:100719. doi:10.1016/j.drup.2020.100719

14. Singh H, Chauhan P, Kakkar AK. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. Eur J Pharmacol. 2021;890:173717. doi:10.1016/j.ejphar.2020.173717

15. Barzkar F, Ranjbar M, Stofofy-Khojine AB, Khajehazad M, Azad RV, Moradi Y, et al. Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies. Med J Islam Repub Iran. 2020;34:171. doi:10.47176/mjiri.34.171

16. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020;6(5):672-83. doi:10.1021/acscentsci.0c00489

17. Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020;35:101647. doi:10.1016/j.tmaid.2020.101647
28. Mothay D, Ramesh KV. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. Virusdisease. 2020;31:194-9. doi:10.1007/s13337-020-00585-z  
29. Das S, Sarmah S, Lyndem S, Roy AS. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn. 2020:1-11. doi:10.1080/07391102.2020.1763201